Anti-Tau dIEE Program

About Innovative NeuroTechnologies

Innovative NeuroTechnologies is a privately held, pre-clinical biotech firm pioneering novel anti-Tau therapies for Alzheimer's and other tauopathies. Operating with a virtual model to minimize overhead, the company is developing a proprietary dual intracellular and extracellular expression (dIEE) technology platform using AAV vectors to deliver anti-Tau antibodies. Led by founder Shawn Mojtahedian, Ph.D., INT has secured non-dilutive NIH SBIR grant funding and is pursuing an orphan drug strategy for specific tauopathies to potentially accelerate regulatory pathways. Its core thesis is that Tau is a more viable therapeutic target than beta-amyloid for modifying disease progression.

Therapeutic Areas